Tandem Diabetes Care shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight rating and raised the price target from $21 to $33.

Benzinga Newsdesk www.benzinga.com Positive 94.9%

Neg 0% Neu 0% Pos 94.9%

Comments

No comments yet. Be the first!